Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.

Scot Garg, Ply Chichareon, Norihiro Kogame, Kuniaki Takahashi, Rodrigo Modolo, Chun-Chin Chang, Mariusz Tomaniak, Farzin Fath-Ordoubadi, Richard Anderson, Keith G Oldroyd, Rod H Stables, Neville Kukreja, Saqib Chowdhary, Gavin Galasko, Stephen Hoole, Azfar Zaman, Christian W Hamm, Philippe G Steg, Peter Jüni, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma & Patrick W Serruys
OBJECTIVE To investigate the impact of different anti-platelet strategies on outcomes after percutaneous coronary intervention (PCI) in patients with established cardiovascular disease (CVD). METHODS GLOBAL LEADERS was a randomized, superiority, all-comers trial comparing one-month dual anti-platelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9-eluting stent. Established CVD was defined as ≥1 prior...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.